Rapamycin vs Metformin for Longevity

The two most-discussed off-label geroprotector drugs. Different mechanisms, different evidence bases, different appropriate users.

Evidence and pricing are current as of May 2026; new trials may change the picture.

Executive Summary

Rapamycin (sirolimus) and metformin are the two off-label drugs most often discussed in the longevity optimization conversation. Both have substantial preclinical evidence for healthspan or lifespan benefit, both have been the subject of ongoing human clinical trial programs, and both are prescribed off-label by physicians focused on aging-related medicine. The conversation about whether one or the other is the right choice for an individual patient is one of the most active questions in the optimization community.

The honest 2026 framing is that these are not interchangeable drugs targeting the same biology. Rapamycin inhibits mTORC1, the central nutrient-sensing kinase that drives anabolic processes and inhibits autophagy. Metformin activates AMPK, the opposing energy-sensing kinase that drives catabolic processes including autophagy. The downstream biology overlaps in places (both increase autophagy, both modulate aging-relevant pathways) but the mechanisms are pharmacologically distinct, and the appropriate patients, dosing patterns, side-effect profiles, and evidence bases differ substantially.

Rapamycin has the larger preclinical animal-lifespan signal — the Interventions Testing Program at the NIH has shown rapamycin to extend mouse lifespan more consistently and substantially than any other intervention tested. The human evidence base is much smaller, with the PEARL trial (the first prospective placebo-controlled rapamycin trial for healthy aging) reporting initial results 2024-2025 and the broader off-label-prescribing population continuing to accumulate observational data. Metformin has the larger human evidence base, particularly through cardiovascular outcomes and diabetes population data, but a smaller preclinical lifespan signal. The TAME trial (Targeting Aging with Metformin) was designed to be the definitive metformin longevity trial; funding and progress have been complicated.

What the evidence supports today:

• Rapamycin has the largest preclinical animal-lifespan signal of any tested intervention; human translation is in early stages.
• Metformin has the largest human evidence base for cardiovascular and metabolic outcomes; the dedicated longevity trial (TAME) has been slow to advance.
• The two drugs target opposing pathways (mTOR vs AMPK) and are not interchangeable; the right choice depends on patient context and risk tolerance.

Mechanism — Opposing Pathways

mTORC1 (mechanistic target of rapamycin complex 1) and AMPK (AMP-activated protein kinase) are two opposing master regulators of cellular energy balance:

• mTORC1 is activated by nutrient availability (amino acids, growth factors, glucose) and drives anabolic processes — protein synthesis, lipid synthesis, ribosome biogenesis, cell growth. mTORC1 also inhibits autophagy. Chronic mTORC1 activation is associated with aging biology including senescence, reduced autophagy, and decreased stress resistance.
• AMPK is activated by low cellular energy (high AMP/ATP ratio) and drives catabolic processes — autophagy, mitochondrial biogenesis, glucose uptake. AMPK opposes mTORC1 activity and is the central downstream mediator of many geroprotective interventions including caloric restriction, exercise, and the AMPK-activator drugs.

Rapamycin directly inhibits mTORC1. Metformin activates AMPK (primarily via mitochondrial complex I inhibition raising AMP/ATP ratio). Both pathways converge on autophagy enhancement — autophagy is the cellular self-degradation and recycling process that selectively clears damaged organelles, misfolded proteins, and dysfunctional cellular components, and is one of the most consistent mechanistic links between geroprotective interventions and aging biology.

The pathways are not redundant. Rapamycin's mTORC1 inhibition produces effects on protein synthesis, cell growth, and immune function that metformin does not produce. Metformin's effects on hepatic gluconeogenesis, gut microbiome, and insulin sensitivity are not produced by rapamycin. The two drugs have overlapping but distinct biology.

The Animal Lifespan Evidence

The Interventions Testing Program (ITP) is the gold-standard animal lifespan testing program for aging interventions, run by the NIA at three independent sites with rigorous methodology. The ITP findings on these two compounds:

• Rapamycin has extended median and maximum lifespan in genetically diverse mice across multiple ITP studies, with effect sizes substantially larger than any other intervention tested. Late-life intervention (starting at 600 days) still extended lifespan, an important finding because it suggests the geroprotective effect does not require lifelong administration.
• Metformin did not extend lifespan in the ITP mouse studies despite its substantial preclinical and clinical literature for metabolic benefit. The metformin lifespan literature in humans is more substantial than in animals; the discrepancy between animal lifespan data and human cohort studies is striking and incompletely understood.

The animal data favor rapamycin substantially. The translation to humans is the question, and the human evidence base — particularly for hard outcomes like mortality — is much smaller for rapamycin than for metformin.

The Human Evidence

Metformin in Humans

Metformin's human evidence base is enormous. The UKPDS and DPP trials established efficacy in T2D and prevention. Multiple large observational cohorts have shown lower all-cause mortality in metformin users vs non-users, even adjusting for diabetes status. The TAME trial was designed to be the first dedicated trial of metformin specifically for aging-related outcomes — it has been slow to advance due to funding and design questions but remains the most consequential pending human trial in geroscience.

For human cardiovascular and metabolic outcomes, metformin has substantially more data than rapamycin.

Rapamycin in Humans

Human use of rapamycin (sirolimus) has been primarily in transplant medicine and rare cancer indications. Off-label use for healthy aging has grown substantially since approximately 2017 in concierge medicine and online prescribing channels. The PEARL trial — Participatory Evaluation of Aging With Rapamycin for Longevity — was the first prospective randomized placebo-controlled trial of rapamycin in healthy older adults, with results reported in 2024–2025 showing modest improvements in muscle function and body composition with intermittent rapamycin dosing (5–10 mg weekly).

The PEARL results are important but modest. The trial was small (~150 participants), short (48 weeks), and used surrogate functional endpoints rather than hard outcomes. Multiple additional human trials are in design or recruitment, and the next 3–5 years will likely produce substantial new human evidence for rapamycin in healthy aging.

Side Effects and Practical Differences

The Stacking Question

Some longevity-focused patients use both drugs in combination — typically metformin daily plus rapamycin weekly. The pharmacological rationale is reasonable: rapamycin's mTOR inhibition and metformin's AMPK activation are complementary mechanisms targeting different aspects of nutrient-sensing biology. The clinical evidence for the combination is essentially anecdotal; no controlled human trials have evaluated the combination for hard outcomes. The combination lacks direct human outcomes evidence and should therefore be framed as research-grade self-experimentation rather than evidence-based clinical practice.

How a Clinician Might Frame the Comparison

• Strongest case for metformin: Patient with established cardiometabolic risk (prediabetes, T2D, metabolic syndrome), broad applicability across populations, lowest cost, lowest barrier to access, largest human evidence base. Metformin is the more conservative and better-evidenced choice for general longevity-oriented intervention.
• Strongest case for rapamycin: Patient specifically interested in the mTOR pathway, willing to accept research-grade evidence and higher cost, with access to a knowledgeable prescribing clinician, and without specific contraindications (active infection, planned major surgery, training goals that depend on muscle hypertrophy). Rapamycin has the larger preclinical lifespan signal but a much smaller human evidence base.
• Reasonable case for both: Patient interested in geroscience as research-grade self-experimentation, with appropriate medical supervision, taking either or both with realistic expectations about the limited human evidence. The combination is mechanistically reasonable but unproven clinically.
• Weakest case: Either drug taken in expectation of robustly demonstrated human longevity benefit. The animal data are interesting; the human translation is incomplete. Both drugs are reasonable to explore; neither has the level of human outcome evidence the supplement and biohacker community sometimes implies.

Rapamycin and metformin are not the same drug, do not target the same biology, and are not interchangeable. The decision between them — or to combine them — depends on patient context, evidence-base preference, access, cost, and risk tolerance. Both have a legitimate role in the geroscience conversation; neither has the human outcome evidence to justify confident clinical recommendation for routine use in healthy adults. The honest position is that both are reasonable research-grade interventions with different appropriate users, and the next 3-5 years of human trial data will substantially clarify the picture.

Educational Disclaimer

This monograph is published by Vanguard Optimization as physician-led, evidence-based education. It is not medical advice. We do not prescribe, diagnose, or establish doctor–patient relationships. Decisions about supplementation or medication should be made with the clinician who knows you and your specific clinical situation. The signal-grading and editorial choices in this document represent our best read of the published literature as of May 2026; new data may change them.

Key References

Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009.

Mannick JB, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014.

Kraig E, et al. PEARL trial: Participatory Evaluation of Aging with Rapamycin for Longevity. 2024-2025 results.

Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEJM. 2002. (DPP)

Holman RR, et al. 10-year follow-up of intensive glucose control in T2D. NEJM. 2008. (UKPDS)

Targeting Aging with Metformin (TAME) — ongoing trial documentation.

Interventions Testing Program — multi-site rodent lifespan studies of metformin, rapamycin, and other compounds.